STUDY QUESTION: How and where is pro-ovastacin activated and how does active ovastacin regulate zona pellucida hardening (ZPH) and successful fertilization?
Introduction
Upon fertilization, the mammalian oocyte exocytoses about 4000 cortical granules (CG) (Austin, 1956; Ducibella et al., 1988) during the cortical reaction (Szollosi, 1967; Wessel et al., 2001 ). This causes physico-chemical changes (Inoue and Wolf, 1975) in the extracellular matrix surrounding the egg, called the zona pellucida (ZP), which hardens and thereby gains resilience against mechanical stress (Drobnis et al., 1988) . Zona pellucida hardening (ZPH) occurs within minutes upon plasmogamy (Barros and Yanagimachi, 1971) and renders the egg envelope impermeable for further sperm (Smithberg, 1953; Braden et al., 1954) . Several possible explanations for in vivo ZPH in the mouse have been considered. These include, for example, the impact of zinc sparks emanating from fertilized oocytes (Que et al., 2015 (Que et al., , 2017 and the action of various enzymes released from CG such as ovoperoxidase (Schmell and Gulyas, 1980) or proteases (Gwatkin et al., 1973; Wolf and Hamada, 1977; Huarte et al., 1985 Huarte et al., , 1993 Zhang et al., 1992 ). An additional cause for ZPH observed during conventional IVF was attributed to constituents of the oviductal fluid in several species (Coy and Avilés, 2010; Mondéjar et al., 2013) .
In the mouse Mus musculus the ZP is composed of three major glycoproteins, termed zona pellucida proteins ZP1, ZP2 and ZP3 (Bleil and Wassarman, 1980; Wassarman et al., 2004) . Upon fertilization, ZPH comes along with proteolytic conversion of ZP2 (120 kDa) into ZP2 f (90 kDa + 30 kDa) (Bleil et al., 1981; Moller and Wassarman, 1989 ) at a conserved cleavage site ( 167 LA↓DE 170 ) (Gahlay et al., 2010) . This cleavage impairs sperm-zona attachment and was suggested definitely to prevent polyspermy (Burkart et al., 2012; Avella et al., 2014) . The responsible proteinase was identified as ovastacin, an astacin-family metalloproteinase encoded by the gene Astl (Quesada et al., 2004; Burkart et al., 2012) . Enzymes of the astacinfamily exhibit a unique specificity for peptide bonds amino-terminal of diacidic sequence motifs (Becker-Pauly et al., 2011) . Ovastacin is translated as an inactive zymogen (pro-ovastacin), including a secretory signal peptide (23 aa), a pro-domain (62 aa), the catalytic protease domain (200 aa) and a unique C-terminal domain (150 aa) of unknown structure and function (Quesada et al., 2004; Gomis-Rüth et al., 2012) . The pro-domains of astacin zymogens position an invariant aspartate residue to block the catalytically essential zinc ion and, thus, removal of the pro-domain is required to gain activity (Yiallouros et al., 2002; Guevara et al., 2010) . As shown only recently (Xiong et al., 2017) , the pro-domain contains in addition a signalling sequence ( 52 DKDIPAIN 64 ), which targets ovastacin to the CG via the regulated secretory pathway. ZP2 cleavage by ovastacin seems to be closely linked to ZPH, since the knockout of fetuin-B, a highly specific inhibitor of ovastacin, results in precocious ZPH before fertilization and causes female infertility in mice (Dietzel et al., 2013; Stöcker et al., 2014) . Fetuin-B was detected in silico (Olivier et al., 2000) , verified as a liver-derived plasma protein (Denecke et al., 2003) , and eventually identified as a potent inhibitor of ovastacin that is also is present in the follicular fluid (Dietzel et al., 2013) . Fetuin-B-deficient oocytes undergo ZP2 into ZP2 f conversion after, not before ovulation (Dietzel et al., 2013) . This suggests that ovastacin needs to be tightly regulated within a narrow time window to ensure successful fertilization.
Apart from triggered release of CG upon fertilization, earlier reports describe pre-mature exocytosis of CG from unfertilized oocytes during IVM, coinciding with germinal-vesicle breakdown and the extrusion of the first meiotic polar body during ovulation (Okada et al., 1986; Ducibella et al., 1988 Ducibella et al., , 1990 . Pre-mature release of ovastacin has also been suggested to be the reason for infertility of fetuin-B deficient female mice (Dietzel et al., 2013) . Addition of fetuin-B during IVF partially prevented ZPH and improved the fertilization rate (Schroeder et al., 1990; Dietzel et al., 2017) . However, despite reduced ZPH in fetuin-B treated oocytes, there was no evidence of increased polyspermy , contrasting the view that ZP2 cleavage is essential for preventing polyspermy (Burkart et al., 2012; Avella et al., 2014; Dean, 2014) .
Besides its function in ZP2 cleavage, ovastacin was also described as a sperm binding partner anchored to the oolemma and termed SAS1B (sperm acrosomal SLLP1 binding protein; SLLP, sperm lysozyme like protein) (Sachdev et al., 2012; Pires et al., 2013 Pires et al., , 2015 . At first glance, this contradicts the ovastacin function as a secreted ZP2-cleaving proteinase. In this context the so far unknown activation process of proovastacin appears to be of significant importance. Many astacins are activated extracellularly by trypsin-like serine proteases (Yiallouros et al., 2002; Guevara et al., 2010; Arolas et al., 2012) . In vitro, this was also shown for pro-ovastacin (Karmilin et al., unpublished data). However, it is currently unknown how and where (extra or intracellularly) pro-ovastacin is activated in vivo. We reasoned that intracellular proteolytic activation might separate the sperm binding from the enzymatic activity of ovastacin, resolving the seemingly conflicting spatial and temporal distribution of ovastacin.
Here we report the intracellular activation of pro-ovastacin and a physiological partial cleavage of ZP2 before fertilization in vitro and in vivo, causing partial ZPH without loss of fertility. Furthermore, we show that the C-terminal domain of pro-ovastacin remains attached to the plasmalemma after active ovastacin release. Recombinant ovastacin, c-terminal domain of ovastacin and fetuin-B
Materials and Methods

Animals-ethical approval
Recombinant full-length murine ovastacin (UniProt Database accession: Q6HA09) and fetuin-B (UniProt: Q9QXC1) were expressed and purified as published (Dietzel et al., 2013) . The construct encoding the C-terminal domain of murine ovastacin (aa 286-435) with a 5′-signalsequence of murine fetuin-B (aa 1-18), a 3′-Strep-tag-sequence and a KpnI restriction-site, was custom-cloned into the pFastBac1 vector (Thermo Fisher, Waltham, USA). Expression and purification were performed as for full-length ovastacin (Dietzel et al., 2013) .
Antibodies
Polyclonal rabbit anti-propeptide and anti-full-length-ovastacin antibodies were generated against the murine ovastacin-derived peptide 34 CSTSVPEGFTPEGSPVFQDK 53 and full-length recombinant mouse ovastacin, respectively. Antisera were diluted 1:10 000 for immunoblot and 1:200 for immunohistochemistry. Anti-pro-catalytic-domain antibodies (anti-pro-cat) were generated by pre-absorption of antifull-length-ovastacin antibodies with the recombinant C-terminal domain of murine ovastacin (10-times incubation over night at 4°C followed by centrifugation for 2 h at 10 000 × g). The supernatant of hybridomas producing the monoclonal anti-mZP2 antibody (IE-3), raised against the N-terminal region of murine ZP2 (aa114-129) (East and Dean, 1984) was diluted 1:10 for immunoblot analysis.
Oocyte and embryo collection
For superovulation 6-to 8-week-old female mice were stimulated by i. p. injection of 5IU pregnant mares serum gonadotropin (Intergonan ® ,
Intervet GmbH, Unterschleißheim, Germany). 48 h later the ovulation was stimulated by i.p. injection of 5 IU hCG (Ovogest ® , Intervet GmbH). 14 h post-hCG the mice were sacrificed and the cumulus oocyte complexes (COCs) isolated from the ampulla. For isolation of pre-ovulation (GV intact) oocytes, the mice were sacrificed at the time of the second hormone application as described (Dietzel et al., 2013) . For isolation of in vivo fertilized oocytes females were mated upon hCG application and sacrificed 12 h post coitum. Oocytes were denuded for immunoblot and ZP digestion by hyaluronidase (0.3 mg/ml H4272, Sigma-Aldrich, Taufkirchen, Germany) for 3-5 min in human tubular fluid (HTF)-Medium and washed three times. Incubations were performed at 37°C and 5% CO 2 in air under mineral oil (M5310, SigmaAldrich).
Oocyte activation and cortical granule exudate extraction
Oocytes were activated for 10 min with 2.5 μM calcium ionophore A23187 (Sigma-Aldrich) in human tubal fluid-Medium (HTF) without bovine serum albumin (BSA) (Gwatkin et al., 1976; Tawia and Lopata, 1992) . For ZP digestion the oocytes were washed twice in HTF without BSA and incubated for 20 min at 37°C to allow ZP2 cleavage. Cortical granule exudate was precipitated for immunoblot analysis with 10% (v/v) trichloroacetic acid and resuspended in sample-buffer.
IVF and embryo culture
Incubations were performed at 37°C and 5% CO 2 in air under mineral oil. Sperm from 12-to 16-week-old males were collected from the cauda epididymis and incubated for 60 min in Toyoda-Yokohama-Hosimedium. Sperm were mixed with up to six COCs in HTF-medium to about 1 × 10 6 sperm/ml for 4 h. Fertilization rate was determined after 24 h. For SDS-PAGE oocytes/embryos were washed three times in HTF-medium without BSA.
ZP digestion assay
To measure the ZPH, ZP digestion using 2 mg/ml α-chymotrypsin (C4229, Sigma-Aldrich) in PBS (0.1% (w/v) PVA (polyvinylalcohol), 1 mM CaCl 2 ) was performed as reported (Gulyas and Yuan, 1985) . ZP dissolution time was determined for each oocyte. Experiments were performed in triplicates with at least 20 oocytes.
SDS-PAGE and immunoblot analysis
Oocytes or 2-cell embryos were lysed in sample-buffer (187.5 mM Tris, 6% (w/v) SDS, 30% (v/v) glycerol, 1.25 M dithiothreitol, pH6.8), instantly upon preparation, applied to 12% (w/v) Tris-glycine polyacrylamide gels and separated at 180 V in running buffer ( PVDF-membranes were incubated with the secondary horseradish peroxidase-coupled anti-rabbit-IgG antibody (Dianova, Berlin, Germany) or anti-rat-IgG antibody (Thermo Fisher, Waltham, USA), respectively, for 1 h at RT in TBS-T with 5% (w/v) SKM. For detection the Biorad (Hilden, Germany) Clarity ImmunoECL solution was used.
Immunofluorescence and microscopy
All steps were performed at RT in PBS containing 0.1% PVA. Cumulus-free MII oocytes and embryos were fixed in PBS with 2% (w/v) paraformaldehyde (PFA) for 1 h, saturated with 0.1 M glycine for 1 h, followed by permeabilization with PBS-T (0.4% (v/v) Tween ® 20) for 10 min and blocked with 10% (v/v) goat serum for 1 h.
Oocytes and embryos were incubated with the primary antibody over night at 4°C in PBS-T with 0.3% (w/v) BSA. After washing three times with PBS-T, oocytes and embryos were incubated with Alexa Flour ® 488-conjugated goat-anti-rabbit IgG (Thermo Fisher) 1:400 for 1 h in PBS-T with 0.3% (w/v) BSA, washed three times in PBS-T and mounted in Mowiol 4-88 medium (Carl-Roth GmbH, Karlsruhe, Germany) containing 0.5 μg/ml DAPI (4.6-diamidino-2-phenyl-indole) and 25 mg/ml DABCO (1.4-diazabicyclo-[2.2.2]-octane) as specified by the manufacturer. If the samples were not permeabilized, all steps were performed in PBS. Images were obtained on a Leica DM6000B microscope with 100-fold magnification (NA 1.40) using the manufacturer's software and deconvoluted using Huygens Core Software (Scientific Volume Imaging, Hilversum, Netherlands). In all fluorescence microscopic images, brightness and contrast were adjusted equally via ImageJ (Schneider et al., 2012) . Brightness and contrast of immunoblots have not been adjusted to remove background signal.
Statistical analysis
Experimental data were statistically pre-analyzed, using Shapiro-Wilk test for normal distribution. In case of normal distribution, significance was determined by two-sided Student's t-test, in case of non-normal distribution, via Mann-Whitney U-test. A value of P < 0.05 was considered as significant.
Results
Intracellular activation of ovastacin
Unfertilized mature metaphase II (MII) oocytes contained both intact full-length pro-ovastacin and proteolytically processed ovastacin (Fig. 1) . The intact pro-ovastacin migrated as a band at 44 kDa, consisting of propeptide, catalytic domain, and C-terminal domain. We also detected a shorter form with a molecular mass of 29 kDa. The anti-propeptide antibody only detected the 44 kDa band, the anti-fulllength-ovastacin antibody detected both bands (Fig. 1) indicating that the 29 kDa form lacked the propeptide (7 kDa) and part of the C-terminal domain (8 kDa). The cortical granule exudate, i.e. supernatant from oocytes after cortical reaction, revealed the same pattern, indicating that ovastacin is exocytosed as partly activated enzyme. Knockout controls proved the specificity of ovastacin antibodies (Fig. 1) .
To scrutinize this result, zonae pellucidae of MII oocytes were digested using α-chymotrypsin, which is an established test for ZP robustness (Gulyas and Yuan, 1985) (Fig. 2A) , resulting in prolonged digestion times in hardened ZP. Compared to unfertilized oocytes with a digestion time of 18.8 ± 7.3 min (mean ± SD, n = 137), oocytes activated by Ca 2+ ionophore A23187 had a digestion time of 35.2 ± 3.2 min (mean ± SD, n = 107), which was almost the same as for 2-cell embryos (36.7 ± 1.2 min; mean ± SD, n = 109), indicating that the Ca 2+ ionophore readily triggered the cortical reaction and, thus, ZP2
cleavage in the absence of sperm. A23187 triggered ZP2 cleavage was inhibited by fetuin-B (19.6 ± 6.2 min; mean ± SD, n = 79), underscoring that measured ZPH was a result of ZP2 cleavage by ovastacin (Dietzel et al., 2013 Floehr et al., 2017) . We added serine proteinase (Pefabloc ® SC) and cysteine proteinase (E64) inhibitors to the medium in order to inhibit potential extracellular activators and to ensure that the activity was due to intracellularly activated ovastacin and not to the activation of pro-ovastacin by extracellular proteases.
However, the digestion times did not vary significantly, independent of the presence of protease inhibitors (34.9 ± 2.4 min, mean ± SD, n = 110 and 35.2 ± 3.2 min, mean ± SD, n = 107, respectively), indicating that ovastacin was not activated outside the cell. These results were confirmed by immunoblot analysis: ZP2 cleavage was increased in activated oocytes with protease inhibitors compared to untreated unfertilized oocytes (Fig. 2B) .
Ovastacin partially cleaves ZP2 before fertilization, but does not affect polyspermy
The strong inhibition of ovastacin by fetuin-B prevented ZPH before fertilization and had been recognized as prerequisite for maintaining mammalian fertility (Dietzel et al., 2013 . However, the ZP of unfertilized wild-type MII oocytes proved to be much more resistant to proteolytic digestion (18.8 ± 7.3 min) than the ZP of ovastacindeficient MII oocytes (1 min) ( Fig. 2A) , indicating partial cleavage of ZP2 by ovastacin (Fig. 2B ) and partial ZPH prior to fertilization. Preovulation germinal vesicle (GV) intact oocytes did not display partial cleavage of ZP2 (Fig. 2B ), confirming that this cleavage was not an artefact of oocyte isolation, but occurred during natural ovulation in vivo. Unexpectedly, the fertilization success as such was not affected, despite increased mechanical oocyte resilience triggered by this prefertilization cleavage (Fig. 2C ). In vivo, there was no decrease in the fertilization rate of ovastacin-deficient oocytes compared to the wildtype (Fig. 2C ) and in vitro, ovastacin-deficient oocytes had even a higher fertilization rate (P = 0.043; Fig. 2C ) than wild-types. Therefore, analyzing fertilization itself is not sufficient to explain the significant decrease in fecundity of ovastacin-deficient mice (P < 0.0001; Fig. 2D ).
Localization of ovastacin upon fertilization
The localization and release of ovastacin was assessed by immunofluorescence microscopy (Fig. 3) . The signal of the propeptide disappeared upon fertilization, indicating pro-ovastacin to ovastacin conversion. However, the catalytic and C-terminal domain were detectable-albeit in reduced quantities-up to the 2-cell embryo stage (Fig. 3) . Notably, non-permeabilized MII oocytes revealed the same staining pattern (Fig. 4C2 ) as permeabilized MII oocytes (Fig. 3) , suggesting that residual ovastacin seemed to be located at the extracellular face of the plasmalemma. To clarify, which part of ovastacin accounts for this residual signal, we sequentially pre-absorbed the antifull-length-ovastacin antibodies by adding the purified recombinant C-terminal domain of murine ovastacin (Fig. 4A ). This pre-absorbed anti-pro-cat antibody detected both isoforms of the recombinant proovastacin (54 and 46 kDa), but not the C-terminal domain (Fig. 4B) . Images of unfertilized permeabilized MII oocytes obtained with either anti-pro-ovastacin or anti-pro-cat antibody did not exhibit significant differences (Fig. 4C1) , ensuring the comparability of the antibodies. However, in the embryos, we observed much lower signal intensity (P = 0.019) with the anti-pro-cat antibody (Fig. 4C3) , indicating that only the C-terminal domain remained at the outer surface of the plasmalemma. The C-terminal domain was also detected in unfertilized MII oocytes (P = 0.00038) in the area of the oolemma surrounding the first polar body (Fig 4C2) . These results suggested that the C-terminal domain of ovastacin accumulated at the outer surface of the plasmalemma, regardless of the time of ovastacin release. We also tested the antibody raised against the C-terminal domain of ovastacin 
Discussion
Several lines of evidence indicate the importance of limited proteolysis for ZPH in mammalian oocytes after fertilization. As a measure of ZPH, proteolytic in vitro ZP digestion has been established to distinguish freshly ovulated, unfertilized 'soft' eggs from robust 2-cell embryos (Smithberg, 1953; Braden et al., 1954) . A key event during zona conversion is the cleavage of ZP2 by the cortical granule (CG) metalloproteinase ovastacin at a strictly conserved site (Burkart et al., 2012) . ZPH is absent in ovastacin-deficient mice ( Fig. 2A) and can be prevented during IVF upon addition of the highly selective physiological ovastacin-inhibitor fetuin-B (Dietzel et al., 2013) . Hence, the immunodetection of the distinct ovastacin-caused ZP2 f fragments is likewise due to the action of ovastacin and consequently indicative for ZPH (Fig. 2B) . In addition to ovastacin, several serine proteinases including tissue plasminogen activator (tPA) are released from CG upon fertilization and, thus, the tPA/plasmin network is most likely involved in ZP conversion (Wolf and Hamada, 1977; Huarte et al., 1985; Zhang et al., 1992; Coy et al., 2012; Peng et al., 2012) . Indeed, the pro-ovastacin zymogen is readily converted into active ovastacin by trypsin-like serine proteinases in vitro, e.g. by plasmin or-even more efficient-by a combination of plasminogen and tPA (Karmilin et al., unpublished data). Mouse CG contain tPA (Huarte et al., 1985) , but are devoid of plasminogen, which is present in the follicular fluid and oviductal fluid (Canipari et al., 1987; Coy et al., 2012) .
This setup would consistently explain the extracellular activation of ovastacin by tPA-activated plasmin after fertilization. However, here we present evidence for partial intracellular activation of ovastacin before fertilization and the cortical reaction. This was unexpected, since most astacin-proteinase zymogens are activated extracellularly . Other examples for intracellular activation are the BMP1/tolloid-astacins, which process collagens, proteoglycans, growth factors and growth factor antagonists (Gomis-Rüth et al., 2012). The BMP1/tolloid-enzymes are activated by furin-like pro-protein convertases in the trans-Golgi-network (Leighton and Kadler, 2003) . A similar activation process occurring on the regulated secretory pathway could also be involved in the intracellular activation of pro-ovastacin. It would explain observations like precocious ZPH during IVF, even in the absence of potential activators, such as trypsin-like serine proteinases. It remains to be elucidated, whether the intracellular activation of ovastacin in mice, which does not rely on extracellular activators in the oviductal fluid, is occurring also in other species. The limited influence of oviductal fluid (Mondéjar et al., 2013) on ZPH in humans and mice appears in agreement with intracellular activation. It also remains to be clarified, whether the hardening effect of the oviductal fluid reported for other species is due to extracellular activation of ovastacin or caused by an entirely different, unknown mechanism, which increases the chance of monospermic fertilization. The partial intracellular activation of ovastacin also might provide a better understanding of the surprising fact that the ZP of freshly ovulated, unfertilized wild-type oocytes turned out to be 'harder' than the ZP of ovastacin-deficient oocytes. This was supported by immunodetection of ZP2 f in wild-type oocytes, whereas Astl -/-oocytes and preovulation wild-type oocytes did not show ZP2 cleavage. The heterogeneously sized cleavage products observed in the immunoblot (Fig. 2C ) are presumably due to additional diacidic ovastacin cleavage sites in the vicinity of the crucial LA*DE-site; this has been already discussed Unfertilized oocytes, non-permeabilized (3) in vivo fertilized embryos, non-permeabilized. n = sample size. Statistical analysis of the fluorescence intensity (integrated density of ROI (grey)) via Mann-Whitney U-test. Pictogram: propeptide (red), catalytic domain (green), C-terminal domain (yellow). (Burkart et al., 2012) . Hence, we present evidence for in vivo prefertilization cleavage of ZP2 in mice. Importantly, this partial zona prehardening does not prevent fertilization by sperm, because the strong inhibition of ovastacin by fetuin-B prevents complete ZPH, thereby maintaining fertility . A slight pre-fertilization cleavage of ZP2 during IVM, even in the presence of serum (and, hence, in the presence of then unknown fetuin-B) had been reported earlier (Ducibella et al., 1990) . Although, a more recent publication (Deng et al., 2003) favoured the view that pre-mature CG exocytosis might be only a minor side effect, occurring concomitantly with the establishment of the cortical granule free domain (CGFD) close to the first polar body. Deng et al. (2003) used the membrane permeating Ca 2+ -chelator BAPTA-AM to ensure the absence of CG exocytosis during CGFD establishment, which was proven by the absence of proteolytic ZP2 to ZP2 f conversion. However, ovastacin, being a zinc-metalloproteinase (which was not known at that time), would be most effectively inhibited by BAPTA-AM (Rosenfeldt et al., 2005) , which binds Zn 2+ much better than Ca 2+ (Stork and Li, 2006) . The absence of ZP2 cleavage had been suggested to be associated to polyspermy (Burkart et al., 2012; Avella et al., 2014; Dean, 2014) . However, contrary to this view, an inactivating mutation of the cleavage site in ZP2 did not cause polyspermy (Gahlay et al., 2010) and even the complete absence of the ZP did not reduce fertilization rate in vitro (Xiong et al., 2017) . Inhibiting ZPH with fetuin-B in vitro likewise did not result in polyspermy and oocytes from ovastacin/fetuin-B double deficient mice bound high numbers of sperm in vitro, but showed no signs of polyspermy . Our results confirm these observations in vivo, demonstrating that ovastacin-deficient zygotes develop normally until the 2-cell stage. Since polyspermy already compromises the development of 2-cell embryos (Clarke and Masui, 1986) , the normal development of 2-cell embryos in the absence of ovastacin, and consequently of ZP2 cleavage, does not seem to significantly affect the rate of polyspermy. It seems undisputable that ZP2 cleavage triggers ZPH and thereby provides a definitive block against polyspermy (Dean, 2014) . However, before this definitive block is installed, the first sperm has fused with the oolemma and triggered a cascade of events excluding further sperm from penetrating the egg's membrane. Recent literature strongly suggests that the sperm protein IZUMO1 and the interacting oocyte protein JUNO (Bianchi et al., 2014) , whose structures were solved recently (Aydin et al., 2016; Han et al., 2016; Ohto et al., 2016) , prevent polyspermy by regulating sperm-oolemma interactions (Wolf and Soper, 1978; Sato, 1979) .
This leaves the question, why ovastacin-deficient mice have only half-sized litters compared to wild-types (Fig. 2D) . Possibly, subfertility of ovastacin-deficient mice might rather be caused by resorption of early embryos devoid of a mechanically robust ZP, as observed in embryos carrying mutations affecting the integrity of the ZP (Liu et al., 1996; Rankin et al., 1996 Rankin et al., , 1999 Rankin et al., , 2001 . The slightly reduced fertilization rate of in vitro fertilized wild-type oocytes could be due to the absence of fetuin-B and caused by ovastacin released from bystander zygotes. Likewise, the significantly higher serum concentration of fetuin-B in mice compared to humans (Denecke et al., 2003) might be an evolutionary adaptation, which-due to higher fecundity in rodents-could protect unfertilized oocytes from ZP2 cleavage caused by ovastacin released from already fertilized eggs (Moller and Wassarman, 1989 ).
In conclusion, we observe in vivo two rounds of ZP2 cleavage, with the first round occurring immediately before or concomitantly with ovulation and the second round being the consequence of the massive burst of ovastacin activity in the cortical reaction. The physiological function of this stepwise hardening remains unclear. However, since ZP-free oocytes have higher IVF rates (Xiong et al., 2017) , the prehardening potentially favours the fittest sperm, effectively introducing a quality control checkpoint for spermatozoa.
Beyond that, we revealed an accumulation of the C-terminal domain of ovastacin at the surface of the plasmalemma, regardless of the time of ovastacin release. These results were confirmed with the anti-Cterminal antibody (Burkart et al., 2012 ) (see supplemental Fig. 1) . In a recent study by (Xiong et al., 2017) using ovastacin C-terminally tagged with mCherry, a remaining C-terminal domain was not observed. This might be due to an impaired binding of the processed C-terminal domain (unprocessed 15 kDa) to the plasmalemma caused by the tag (28.8 kDa).
A membrane-bound protease domain, as proposed based on in silico analysis (Pires et al., 2013) , would render ZP2 cleavage by ovastacin unlikely. This molecular model suggested that the central part of the catalytic proteinase domain of ovastacin might be involved in anchoring the protein within the oolemma (Pires et al., 2013) . However, this would disrupt the active site structure and the substrate binding cleft, which is conserved in astacin proteases (e.g. Bode et al., 1992; Guevara et al., 2010; Arolas et al., 2012) . A membrane-bound Cterminal domain would reconcile these seemingly conflicting data. The C-terminal domain might act as binding partner, whereas the released protease domain could process ZP2. The existence of the 29 kDa catalytically active ovastacin and the residual part of ovastacin Cterminal domain remaining on the embryo plasmalemma would fully support this notion.
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